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Stable Coronary Artery Disease
Raymond Pranata1, Nico Kusuma2, Rachel Vania1, Bambang Budi Siswanto3
Cardiac troponins (cTn) are the preferred biomarkers of myocardial necrosis, usually 
used for diagnosis and risk stratification in acute coronary syndromes. Highly sensitive 
troponin T (hs-cTnT) may be elevated in stable coronary artery disease (SCAD), in 
which subclinical plaque erosion or rupture and distal embolization and subclinical isch-
emic episode. hs-cTnT may be used as a prognostic marker in SCAD and can predict 
cardiovascular events and patient’s mortality rate. In this article, plaque characteristic 
that is linked to hs-cTnT, it’s used as prognostic biomarker and comparison to other 
indicators are the focus of discussion.
(Indonesian J Cardiol. 2018;39:44-9)
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Troponin adalah biomarker yang paling disukai untuk mendeteksi nekrosis miokardium dan untuk mendiagnosis dan stratifikasi risiko pada 
sindrom koroner akut. Highly sensitive troponin T (hs-cTnT) dapat meningkat pada penyakit jantung koroner stabil dimana terjadi ruptur 
plak atau erosi dan embolisasi distal sublklinis, dan episode iskemik subklinis. Sehingga biomarker tersebut dapat digunakan sebagai marker 
prognostik pada penyakit jantung koroner stabil dan dapat memprediksi angka kejadian kardiovaskular dan tingkat mortalitas pasien. Pada 
artikel ini akan dibahas mengenai karakteristik plak yang dihubungkan dengan peningkatan hs-cTnT, pengunaan sebagai biomarker prognostik 
dan serta perbandingan dengan indikator lainnya.
(Indonesian J Cardiol. 2018;39:44-9)
Kata kunci: troponin – biomarker jantung– infark miokardium
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Introduction
Cardiac Troponin T and I are components of cardiomyocyte contractile apparatus and the most widely used biomarker of cardiomyocyte necrosis Troponin measured 
in those with acute coronary syndrome. Studies had 
shown that even slight increase in cardiac troponin 
concentration is associated with worse prognosis in 
those with acute coronary syndrome.1,2
Elevation of cardiac troponin ≥0,01 µg/liter was 
associated with increased mortality in those with or 
without history of cardiovascular events (Table 1). 
Based on this finding, it is probable that increased 
level of troponin which does not pass the threshold 
concentration for positive test (below the limit for 
detection; very low plasma troponin level) may play a 
role as predictor of adverse cardiovascular events.3,4,9
Plasma cardiac troponin is a sensitive and specific 
biomarker which is commonly used to diagnose 
myocardial infarction. The advent of highly sensitive 
troponin T assay (hs-cTnT) enables not only early 
detection of myocardial infarction but also serves as a 
prognostication tool in stable coronary artery disease. It 
was able to detect the concentration of plasma cardiac 
troponin 10 times lower compared to conventional 
assay. Elevation of hs-cTnT above 99 percentiles was 
found in 1/3 patients with stable coronary artery 
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disease diagnosed through computed tomography 
angiography. 5,6,7
Cardiac Troponin and Stable Coronary 
Artery Disease
Concentration of hs-cTnT is higher in those with stable 
coronary artery disease compared to a normal person. 
(Figure 1) Subclinical erosion or plaque rupture and 
distal embolization, subclinical ischemic episode, 
micro-small vessels occlusion, inflammatory process, 
cardiomyocyte apoptosis, reduced renal clearance and 
distention due to pressure or volume overload were 
hypothesized to be the underlying pathophysiology 
of increased troponin and worse outcome.8
A study by Torbjorn Omland, et al. conclude that 
increased concentration of plasma cardiac troponin 
T measured by hs-cTnT was significantly associated 
with increased adverse cardiovascular events and heart 
failure, but not myocardial infarction in patients with 
stable coronary artery disease. This study showed that 
very low plasma cardiac troponin T concentration 
was detectable in the majority of patients with stable 
coronary artery disease and preserved ejection fraction. 
After adjustment for other independent prognostic 
indicators, there was a strong and graded increase 
in the cumulative incidence of cardiovascular death 
and of heart failure in the study group. A study by 
Mirta Diez, et al showed that increased level of highly 
sensitive cardiac troponin (hs-cTn) was directly 
proportional to ventricular dysfunction and those with 
ejection fraction ≤ 45% had higher hs-cTn. Increased 
level of hs-cTn was associated with poor clinical 
outcome, low cardiac output, and cardiogenic shock. 
Cardiomyocyte damage was even more prominent 
during acute exacerbation of heart failure due to 
increase in pulmonary capillary pressure, reduced 
coronary perfusion pressure, increased catecholamine 
secretion, abnormal calcium metabolism, oxidative 
stress and inflammation. This study concluded that 
heart failure caused by coronary artery disease had 
high hs-cTn level compared with heart failure due to 
other etiology. The use of hs-cTn for risk stratification 
Table 1. Association between high-sensitive cardiac troponin T and cardiovascular
outcomes. From Omland et al, A sensitive cardiac troponin T assay in stable coronary
artery disease.9
Figure 1. Distribution and determinants of cardiac troponin T concentration in stable
coronary artery disease and apparently healthy blood donors. From: Omland et al. A
sensitive cardiac troponin T assay in stable coronary artery disease.9
Figure 1. Distribution and determinants of cardiac troponin 
T concentration in stable coronary artery disease and 
apparently healthy blood donors. From: Omland et al. A 
sensitive cardiac troponin T assay in stable coronary artery 
disease.9
Table 1. Association between high-sensitive cardiac troponin T and cardiovascular
outcomes. From Omland et al, A sensitive cardiac troponin T assay in stable coronary
artery disease.9
Figure 1. Distribution and determinants of cardiac troponin T concentration in stable
coronary artery disease and apparently healthy bl od donors. Fr m: Omland et al. A
sensitive cardiac troponin T assay in stable coronary artery disease.9
Table 1. Association between high-sensitive cardiac troponin T and cardiovascular outcomes. From Omland et al, A sensitive 
cardiac troponin T assay in stable coronary artery disease.9
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during admission helps in determining those at high 
risk of death and poor prognosis which helps in guiding 
a more aggressive and emergent therapy.7,9
Plaque Characteristic and Highly 
Sensitive Cardiac Troponin T
Elevated hs-cTnT was not associated with type 
or severity of chest pain and degree of stenosis but 
has a relationship between plaque composition 
especially remodeling in area without calcification 
and smooth or mixed plaque. A study investigated 
about plaque characteristic in non-culprit coronary 
artery with the result showing association between 
segmental plaque volume and virtual histology-
derived thin-cap fibroatheroma (VH-TCFA) with 
elevated concentration of hs-cTnT in patients with 
stable coronary artery disease.8 VH-TCFA was found 
in 49% of the patients with hs-cTnT concentration 
≥14 pg/mL which means that there was 2 times 
more frequent compared to those with hs-cTnT <14 
pg/mL (adjusted OR 2.35, 95% CI: 1.12-4.91, p = 
0.024). VH-TCFA with high lesional plaque volume 
(lesional plaque volume above the median of all le-
sions classified as VH-TCFA) was three times more 
prevalent in those with hs-cTnT concentration ≥14 
pg/mL (adjusted OR 3.36, 95% CI: 1.44 – 7.84, p 
= 0.005).  Normalized segmental plaque volume and 
normalized segmental vessel volume were positively 
correlated with the level of hs-cTnT while there is 
no association between plaque burden and hs-cTnT 
concentration.8 (Table 2) 
A study also showed that elevated pre-procedural 
hs-cTnT concentration ≥14 pg/mL was found in 26% 
of patients with stable coronary disease undergoing 
percutaneous coronary intervention and is associated 
with increased risk of death. It was also an independent 
predictor of all-cause mortality within one year (HR 
5.73; 95% confidence intervals 3.34–9.83; P<0.001; 
adjusted HR 2.08; 95% confidence interval 1.10–3.92; 
P=0.024, after adjustment to relevant risk factors 
including age, gender, and chronic kidney disease).6 
Elevated hs-cTnT was found to be related to cardiac-
cause mortality  (HR 4.68; 95% confidence interval 
2.12–10.31; P<0.001).6 (Table 3)
Highly Sensitive Cardiac Troponin T 
compared to other indicators
Heart and Soul Study compared traditional risk 
factors (age, gender, body mass index, hypertension, 
dyslipidemia, and diabetes) and biomarkers (NT-
proBNP, hs-cTnT and urine albumin:creatinine ratio) 
in predicting risk of secondary events (secondary events 
in those with coronary heart disease) in patient with 
stable coronary artery disease. The top four indicators 
were NT-proBNP, hs-cTnT, urine albumin:creatinine 
ratio, and smoking.10 From traditional and novel 
biomarker risk factors, elevated hs-cTnT was the 
second most powerful predictor of cardiovascular Table 2. Association between high-sensitivity cardiac troponin T and plaque characteristics in non-
culprit stable coronary artery disease. From: Oemrawsingh RM et al. High-sensitivity troponin T in
relation to coronary plaque characteristics in patients with stable coronary artery disease; results of
the ATHEROREMO-IVUS study.8
Table 3. One year outcome in patients with and without elevated hs-
cTnT From: Zanchin T, et al. Preprocedural high-sensitivity cardiac
troponin T and clinical outcomes in patients with stable coronary artery
Table 2. Association between high-sensitivity cardiac troponin T and plaque characteristics in non-culprit stable 
coronary artery disease. From: Oemrawsingh RM et al. High-sensitivity troponin T in relation to coronary plaque 
characteristics in patients with stable coronary artery disease; results of the ATHEROREMO-IVUS study.8
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events (adjusted HR 1.47, 95% CI 1.18-1.84); p = 
0.001) behind smoking.
Prognostic value of hs-cTnT measurement is 
also influenced by various factors. A study by Carda 
et al showed that elevated hs-cTnT was associated 
with increased risk of the primary outcome (RR 
2.360; p = 0.001) and heart failure (RR 5.932; p < 
0.001) but not with acute ischemic events, however, 
it’s significance is lost after controlling with age. Its 
significance is also affected by ejection fraction <40%, 
use of anticoagulant and ACE inhibitor. Carda et al 
also stated that other studies did not include patients 
with EF <40% as study sample which means that it’s 
clinical significance are questionable in those with 
heart failure reduced ejection fraction. (Table 4) Carda 
et al also stated that their study is in agreement with 
ESC guideline for management of stable coronary 
artery disease in which troponin assay has prognostic 
value but is not enough to be recommended as routine 
systematic examination in stable coronary artery 
disease at outpatient settings.10,11
Conclusion
Subclinical erosion or plaque rupture and distal 
embolization, subclinical ischemic episode, micro-
small vessels occlusion, inflammatory process, 
cardiomyocyte apoptosis, reduced renal clearance and 
distention due to pressure or volume overload were 
hypothesized to be the underlying pathophysiology 
of increased troponin and worse outcome. Highly 
sensitive cardiac troponin T is one of the best 
prognostication tools among traditional and novel 
risk factors to predict of adverse. It helps in gradation 
and risk stratification of those with stable coronary 
artery disease because of its proportionality with 
degree and complexity of coronary atherosclerosis, 
adverse cardiovascular event, and mortality rate.12 
Hs-cTnT is also able to predict acute coronary 
Table 2. Association between high-sensitivity cardiac troponin T and plaque characteristics in non-
culprit stable coronary artery disease. From: Oemrawsingh RM et al. High-sensitivity troponin T in
relation to coronary plaque characteristics in patients with stable coronary artery disease; results of
the ATHEROREMO-IVUS study.8
Table 3. One year outcome in patients with and without elevated hs-
cTnT From: Zanchin T, et al. Preprocedural high-sensitivity cardiac
troponin T and clinical outcomes in patients with stable coronary artery
Table 3. One year outcome in patients with and without 
elevated hs-cTnT 
From: Zanchin T, et al. Preprocedural high-sensitivity cardiac troponin 
T and clinical outcomes in patients with stable coronary artery disease 
undergoing elective percutaneous coronary intervention.6
Table 4. Adjusted multivariable for myocardial infarction, stroke or cardiovascular death in Heart and Soul Risk Model. 
From: Beatty AL, et al. Traditional risk factors versus biomarkers for prediction of secondary events in patients with stable coronary 
heart disease: from the heart and soul study.10
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syndrome, myocardial infarction and mortality in 
those with stable coronary artery disease due to its 
presence in the majority of patients including those 
who are at low risk. Albeit the promising prospect of 
hs-cTnT as a prognostication and risk stratification 
tool for patients with stable coronary artery disease, 
the evidence is still lacking to be recommended in the 
guideline and used routinely in clinical practice. 
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